Skip to main content
Back to homepage
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Menu
Press Releases
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
December 11, 2017
ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301
Download
PDF format download (opens in new window)
December 11, 2017
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-402
Download
PDF format download (opens in new window)
November 15, 2017
ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting
Download
PDF format download (opens in new window)
October 23, 2017
ADC Therapeutics Announces Closing of $200 Million Private Financing to Fund Two Lead Programs Through Registrational Trials
Download
PDF format download (opens in new window)
June 16, 2017
ADC Therapeutics Presents First Clinical Data from its Novel Antibody-Drug Conjugate ADCT-402 at the International Conference on Malignant Lymphoma
Download
PDF format download (opens in new window)
June 16, 2017
ADC Therapeutics Presents Interim Data from the First Clinical Study of its Novel Antibody-Drug Conjugate ADCT-301 at the 14-ICML
Download
PDF format download (opens in new window)
June 09, 2017
ADC Therapeutics will be attending the 14th International Conference on Malignant Lymphoma June 14-17, 2017 in Lugano, Switzerland
Download
PDF format download (opens in new window)
June 09, 2017
ADC Therapeutics Receives Orphan Drug Designation for ADCT-402 for the Treatment of Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Download
PDF format download (opens in new window)
May 19, 2017
ADC Therapeutics Doses First Patient in a Phase I Clinical Trial of ADCT-502 in Patients with Advanced Solid Tumors with HER2 Expression
Download
PDF format download (opens in new window)
March 30, 2017
ADC Therapeutics Presents Pre-Clinical Data for Two Investigational ADCs at the American Association for Cancer Research Annual Meeting
Download
PDF format download (opens in new window)